PharmaRadar360

PharmaRadar360

🌍·15h agoResearch

Comparative efficacy and safety of CD19 chimeric antigen receptor T-cell therapy versus CD3/CD20 bispecific antibodies in relapsed/refractory mantle cell lymphoma: a meta-analysis of clinical trials and real-world studies

Publisher

C
Crossref

Global

This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
Crossref
Region
Global
Scope
Research
Published
September 23, 2026
Language
EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.

Source route

Continue on doi.org

Leave the platform to read the original full article on the publisher site.

Source: Crossref

Scope: Research

Open original article
Comparative efficacy and safety of CD19 chimeric antigen receptor T-cell therapy versus CD3/CD20 bispecific antibodies in relapsed/refractory mantle cell lymphoma: a meta-analysis of clinical trials and real-world studies | PharmaRadar360